ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Feb 07, 2019 15:30 JST
Source:
Sanofi
Sanofi delivers 2018 business EPS growth of 5.1% at CER
PARIS, FRANCE, Feb 07, 2019 - (ACN Newswire) - Sanofi announced the 2018 fourth-quarter and full-year results.
Fourth-quarter sales growth driven by Specialty Care and Vaccines
- Net sales were EUR8,997 million, an increase of 3.5% on a reported basis, 3.9% at CER and 2.6% at CER/CS.
- Sanofi Genzyme sales were up 37.4% (16.1% at CER/CS), led by Immunology and Rare Blood Disorder franchises.
- Vaccines sales increased 9.7%, driven by successful influenza differentiation strategy and Menactra(R).
- CHC sales increased 1.9%, supported by Emerging Markets.
- DCV GBU sales were down 11.3%; Global Diabetes franchise sales declined 10.5% in line with 2015-2018 guidance.
- Emerging Markets sales were up 6.0%, reflecting strong performance in Asia.
Full-Year 2018 sales growth from new products and Emerging markets more than offset impact of U.S. LoEs
- Net sales in 2018 were EUR34,463 million, down 1.7% on a reported basis and grew 2.5% at CER (up 0.6% at CER/CS).
- Sanofi Genzyme grew 30.8% (+14.2% at CER/CS) to EUR7,226 million.
- Vaccines sales increased 2.4% to EUR5,118 million while CHC sales were up 3.0% to EUR4,660 million.
- DCV GBU sales declined 13.8% to EUR4,511 million.
- Emerging Markets sales were up 7.5%, supported by strong performance in China (up 12.7%).
Sanofi delivers 2018 business EPS at the high end of its guidance range
- Q4 2018 business EPS up 4.7% at CER to EUR1.10.
- Full-Year 2018 business EPS of EUR5.47 up 5.1% at CER and IFRS EPS of EUR3.45 (down 48.5%).
- Board proposes dividend of EUR3.07, the 25th consecutive increase in dividend.
Key achievements in sustaining innovation in R&D
- Isatuximab met primary endpoint of ICARIA phase 3 study in Relapsed/Refractory Multiple Myeloma.
- BIVV001 demonstrated sustained high factor levels at once-weekly dosing with data presented at ASH.
- FDA Priority Review granted for Dupixent(R) in adolescents with moderate-to-severe atopic dermatitis.
- R&D strategy evolves towards prioritization of Specialty Care and Vaccines, leveraging technology platforms and data science.
2019 financial outlook
- Sanofi expects 2019 business EPS to grow between 3% and 5% at CER, barring unforeseen major adverse events. Applying average January 2019 exchange rates, the positive currency impact on 2019 business EPS is estimated to be between 1% to 2%.
Sanofi Chief Executive Officer, Olivier Brandicourt, commented:
"In the fourth quarter, we continued the momentum of the previous quarter and we delivered 5% full-year business EPS growth, at the high end of our guidance. In 2018, we executed on important launches including Dupixent(R), Libtayo(R) and Cablivi(R), as the headwinds from our U.S. LoEs began to moderate. Additionally, the acquisitions of Bioverativ and Ablynx provided the foundation to build a leading Rare Blood Disorder franchise and to enhance our biologic discovery capabilities. As we enter 2019, our focus remains on delivering our business priorities and transforming Sanofi to address the evolving business dynamics facing our industry."
Q4 2018 Results:
http://hugin.info/152918/R/2233891/878937.PDF
Investor Relations:
+33 1 53 77 45 45
E-mail:
IR@sanofi.com
Media Relations:
+33 1 53 77 46 46
E-mail:
MR@sanofi.com
Website: www.sanofi.com
Mobile app: SANOFI IR available on the App Store and Google Play
Source: Sanofi
Sectors: Science & Research, BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Sumitomo Metal Mining and Mitsubishi Corporation to Participate in Kalgoorlie Nickel Project - Goongarrie Hub
Apr 30, 2024 19:08 JST
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
Apr 30, 2024 18:00 JST
Q&M Dental Enhances Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore
Apr 30, 2024 17:25 JST
SPARX Group Establishes Space Frontiers Second Fund
Apr 29, 2024 18:49 JST
MHI Establishes Local Subsidiary "Mitsubishi Heavy Industries Vietnam"
Apr 29, 2024 18:00 JST
POSCO Future M and Honda Reach Basic Agreement on Collaboration for Production of Cathode Materials for Automotive Batteries in Canada
Apr 29, 2024 14:25 JST
Honda Plans to Establish Comprehensive Electric Vehicle Value Chain in Ontario, Canada
Apr 29, 2024 14:16 JST
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
More Latest Release >>
Related Release
The 16th Annual Global CSR & ESG Summit and Awards 2024: Celebrating Sustainable Leadership and Innovation, 25 April 2024
April 30 2024 19:40 JST
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
December 06 2022 14:00 JST
Sanofi Renews Partnership with Cielo to Strengthen its Talent Acquisition Strategy in Asia
April 19 2021 09:00 JST
Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
April 26 2019 13:30 JST
Sanofi Delivers 2017 Business EPS in line with Guidance
February 07 2018 15:00 JST
Sanofi to Acquire Bioverativ for $11.6 Billion
January 22 2018 14:00 JST
Sanofi: Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent(R) (alirocumab)
October 06 2017 08:00 JST
A*STAR, NUS and NUH Join Forces to Understand Immune Erosion in Elderly
February 13 2014 11:30 JST
More Press release >>